Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Soleus

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 15, 2023 1:10pm

77 Views

Post# 35737262

RE:RE:Soleus

Insider number SMUSUME001

palinc2000 wrote:
They are still listed on Sedi.ca as insiders with more than 10% of outstanding shares so there appears to be a mistake on Fintel

LouisW wrote: Based on the latest information, Soleus sold all the shares they had in Q3.

https://fintel.io/so/ca/th/soleus-capital-management-l-p

However, when I look into the insider section of Stockhouse, Soleus acquired lots of shares in Q3 and ended up the largest shareholder and insider.

I am confused...the information I found is paradoxical. BTW, Morgan Stanley haven't disclosed the details. And Taimed sold a lot in Q3.